Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/26/24
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024GlobeNewsWire • 08/15/24
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)GlobeNewsWire • 08/15/24
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ETGlobeNewsWire • 08/01/24
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across EuropeGlobeNewsWire • 07/22/24
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024GlobeNewsWire • 07/01/24
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in EuropeGlobeNewsWire • 06/18/24
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024GlobeNewsWire • 05/29/24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateGlobeNewsWire • 05/21/24
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKGlobeNewsWire • 05/21/24
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.GlobeNewsWire • 05/21/24
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.Business Wire • 05/21/24